These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23832667)

  • 1. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.
    Wu YM; Liu CH; Huang MJ; Lai HS; Lee PH; Hu RH; Huang MC
    Cancer Res; 2013 Sep; 73(17):5580-90. PubMed ID: 23832667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C1GALT1 promotes invasive phenotypes of hepatocellular carcinoma cells by modulating integrin β1 glycosylation and activity.
    Liu CH; Hu RH; Huang MJ; Lai IR; Chen CH; Lai HS; Wu YM; Huang MC
    PLoS One; 2014; 9(8):e94995. PubMed ID: 25089569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
    Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
    Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
    Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
    Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2.
    Hung JS; Huang J; Lin YC; Huang MJ; Lee PH; Lai HS; Liang JT; Huang MC
    Oncotarget; 2014 Apr; 5(8):2096-106. PubMed ID: 24758762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic significance and function of S-phase kinase-associated protein 2 overexpression in hepatocellular carcinoma.
    Zhang SH; Qian YM; Liu AW; Cai J; Zhao XL; Wei JJ; Zhu MH
    Hum Pathol; 2012 Jul; 43(7):1084-93. PubMed ID: 22204716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
    Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
    Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
    Tan S; Li R; Ding K; Lobie PE; Zhu T
    FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
    Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
    Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.
    Lee SJ; Lee J; Sohn I; Mao M; Kai W; Park CK; Lim HY
    Anticancer Res; 2013 Nov; 33(11):5179-86. PubMed ID: 24222167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.
    Tavian D; De Petro G; Benetti A; Portolani N; Giulini SM; Barlati S
    Int J Cancer; 2000 Sep; 87(5):644-9. PubMed ID: 10925356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
    Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
    Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
    Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
    J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference.
    Xie B; Xing R; Chen P; Gou Y; Li S; Xiao J; Dong J
    J Surg Res; 2010 Aug; 162(2):231-8. PubMed ID: 19765730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
    Nishimura Y; Takiguchi S; Ito S; Itoh K
    Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells.
    Yang H; Magilnick N; Noureddin M; Mato JM; Lu SC
    J Cell Physiol; 2007 Mar; 210(3):766-73. PubMed ID: 17154373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
    Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
    Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
    Kim CH; Kim J; Kahng H; Choi EC
    Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.